# A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies

> **NCT00807677** · PHASE1 · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 31 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- Chronic Myelogenous Leukemia
- Chronic Lymphocytic Leukemia
- Multiple Myeloma
- Waldenstrom's Macroglobulinemia
- Myelodysplastic Syndrome
- Philadelphia Chromosome-negative CML
- Myeloid Metaplasia
- Myelofibrosis
- Advanced Polycythemia
- Non-Hodgkins Lymphoma

## Interventions

- **DRUG:** TAK-901

## Key facts

- **NCT ID:** NCT00807677
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2012-09
- **Final completion:** 2013-03
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2013-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00807677

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00807677, "A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00807677. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*